Bariatric surgery: Shedding the monetary weight of prescription costs in the managed care arena

Chad E. Potteiger, Prakash R. Paragi, Nicholas A. Inverso, Christopher Still, Mary Jane Reed, William Strodel, Marc Rogers, Anthony Petrick

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Background: Prescription costs for treatment of co-morbidities associated with morbid obesity is a considerable annual health-care expenditure. This study addressed the effect of Roux-en-Y gastric bypass (RYGBP) on diabetic and anti-hypertensive pharmaceutical utilization and cost savings at our institution. Methods: Retrospective data from the electronic database of 51 consecutive patients, who underwent RYGBP from March 2001 to May 2002 were studied. Patients had BMI >40 associated with obesity-related diabetes and hypertension. Prescription medications utilized by this cohort were reviewed preoperatively and at 3- and 9-month intervals postoperatively. Significance was analyzed by paired t-test. Results: Prevalence of diabetes and hypertension was 55.7% (29/53) and 44.3% (24/53) respectively, and 34% (18/53) patients had both co-morbidities. Preoperativeiy, patients were on an average of 2.44 ± 1.86 medications at a cost of $187.24 ± $237.41 per month. Postoperatively, the mean number of medications was reduced to 0.56 ± 0.81 agents (P<0.001) at a monthly cost of $42.53 ± 116.60 (P<0.001). Conclusions: RYGBP can decrease the prescription medication requirements, resulting in significant cost-savings in the treatment of obesity-related hypertension and diabetes. This study found a 77.3% reduction in total cost of diabetic and anti-hypertensive medications.

Original languageEnglish (US)
Pages (from-to)725-730
Number of pages6
JournalObesity Surgery
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2004

Fingerprint

Bariatric Surgery
Managed Care Programs
Prescriptions
Gastric Bypass
Weights and Measures
Costs and Cost Analysis
Cost Savings
Hypertension
Antihypertensive Agents
Obesity
Morbidity
Morbid Obesity
Health Expenditures
Health Care Costs
Databases
Delivery of Health Care
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Potteiger, C. E., Paragi, P. R., Inverso, N. A., Still, C., Reed, M. J., Strodel, W., ... Petrick, A. (2004). Bariatric surgery: Shedding the monetary weight of prescription costs in the managed care arena. Obesity Surgery, 14(6), 725-730. https://doi.org/10.1381/0960892041590999
Potteiger, Chad E. ; Paragi, Prakash R. ; Inverso, Nicholas A. ; Still, Christopher ; Reed, Mary Jane ; Strodel, William ; Rogers, Marc ; Petrick, Anthony. / Bariatric surgery : Shedding the monetary weight of prescription costs in the managed care arena. In: Obesity Surgery. 2004 ; Vol. 14, No. 6. pp. 725-730.
@article{b979c1cd08554bacafc8b44f5c006ec6,
title = "Bariatric surgery: Shedding the monetary weight of prescription costs in the managed care arena",
abstract = "Background: Prescription costs for treatment of co-morbidities associated with morbid obesity is a considerable annual health-care expenditure. This study addressed the effect of Roux-en-Y gastric bypass (RYGBP) on diabetic and anti-hypertensive pharmaceutical utilization and cost savings at our institution. Methods: Retrospective data from the electronic database of 51 consecutive patients, who underwent RYGBP from March 2001 to May 2002 were studied. Patients had BMI >40 associated with obesity-related diabetes and hypertension. Prescription medications utilized by this cohort were reviewed preoperatively and at 3- and 9-month intervals postoperatively. Significance was analyzed by paired t-test. Results: Prevalence of diabetes and hypertension was 55.7{\%} (29/53) and 44.3{\%} (24/53) respectively, and 34{\%} (18/53) patients had both co-morbidities. Preoperativeiy, patients were on an average of 2.44 ± 1.86 medications at a cost of $187.24 ± $237.41 per month. Postoperatively, the mean number of medications was reduced to 0.56 ± 0.81 agents (P<0.001) at a monthly cost of $42.53 ± 116.60 (P<0.001). Conclusions: RYGBP can decrease the prescription medication requirements, resulting in significant cost-savings in the treatment of obesity-related hypertension and diabetes. This study found a 77.3{\%} reduction in total cost of diabetic and anti-hypertensive medications.",
author = "Potteiger, {Chad E.} and Paragi, {Prakash R.} and Inverso, {Nicholas A.} and Christopher Still and Reed, {Mary Jane} and William Strodel and Marc Rogers and Anthony Petrick",
year = "2004",
month = "6",
day = "1",
doi = "10.1381/0960892041590999",
language = "English (US)",
volume = "14",
pages = "725--730",
journal = "Obesity Surgery",
issn = "0960-8923",
publisher = "Springer New York",
number = "6",

}

Potteiger, CE, Paragi, PR, Inverso, NA, Still, C, Reed, MJ, Strodel, W, Rogers, M & Petrick, A 2004, 'Bariatric surgery: Shedding the monetary weight of prescription costs in the managed care arena', Obesity Surgery, vol. 14, no. 6, pp. 725-730. https://doi.org/10.1381/0960892041590999

Bariatric surgery : Shedding the monetary weight of prescription costs in the managed care arena. / Potteiger, Chad E.; Paragi, Prakash R.; Inverso, Nicholas A.; Still, Christopher; Reed, Mary Jane; Strodel, William; Rogers, Marc; Petrick, Anthony.

In: Obesity Surgery, Vol. 14, No. 6, 01.06.2004, p. 725-730.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bariatric surgery

T2 - Shedding the monetary weight of prescription costs in the managed care arena

AU - Potteiger, Chad E.

AU - Paragi, Prakash R.

AU - Inverso, Nicholas A.

AU - Still, Christopher

AU - Reed, Mary Jane

AU - Strodel, William

AU - Rogers, Marc

AU - Petrick, Anthony

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Background: Prescription costs for treatment of co-morbidities associated with morbid obesity is a considerable annual health-care expenditure. This study addressed the effect of Roux-en-Y gastric bypass (RYGBP) on diabetic and anti-hypertensive pharmaceutical utilization and cost savings at our institution. Methods: Retrospective data from the electronic database of 51 consecutive patients, who underwent RYGBP from March 2001 to May 2002 were studied. Patients had BMI >40 associated with obesity-related diabetes and hypertension. Prescription medications utilized by this cohort were reviewed preoperatively and at 3- and 9-month intervals postoperatively. Significance was analyzed by paired t-test. Results: Prevalence of diabetes and hypertension was 55.7% (29/53) and 44.3% (24/53) respectively, and 34% (18/53) patients had both co-morbidities. Preoperativeiy, patients were on an average of 2.44 ± 1.86 medications at a cost of $187.24 ± $237.41 per month. Postoperatively, the mean number of medications was reduced to 0.56 ± 0.81 agents (P<0.001) at a monthly cost of $42.53 ± 116.60 (P<0.001). Conclusions: RYGBP can decrease the prescription medication requirements, resulting in significant cost-savings in the treatment of obesity-related hypertension and diabetes. This study found a 77.3% reduction in total cost of diabetic and anti-hypertensive medications.

AB - Background: Prescription costs for treatment of co-morbidities associated with morbid obesity is a considerable annual health-care expenditure. This study addressed the effect of Roux-en-Y gastric bypass (RYGBP) on diabetic and anti-hypertensive pharmaceutical utilization and cost savings at our institution. Methods: Retrospective data from the electronic database of 51 consecutive patients, who underwent RYGBP from March 2001 to May 2002 were studied. Patients had BMI >40 associated with obesity-related diabetes and hypertension. Prescription medications utilized by this cohort were reviewed preoperatively and at 3- and 9-month intervals postoperatively. Significance was analyzed by paired t-test. Results: Prevalence of diabetes and hypertension was 55.7% (29/53) and 44.3% (24/53) respectively, and 34% (18/53) patients had both co-morbidities. Preoperativeiy, patients were on an average of 2.44 ± 1.86 medications at a cost of $187.24 ± $237.41 per month. Postoperatively, the mean number of medications was reduced to 0.56 ± 0.81 agents (P<0.001) at a monthly cost of $42.53 ± 116.60 (P<0.001). Conclusions: RYGBP can decrease the prescription medication requirements, resulting in significant cost-savings in the treatment of obesity-related hypertension and diabetes. This study found a 77.3% reduction in total cost of diabetic and anti-hypertensive medications.

UR - http://www.scopus.com/inward/record.url?scp=3242810485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242810485&partnerID=8YFLogxK

U2 - 10.1381/0960892041590999

DO - 10.1381/0960892041590999

M3 - Review article

C2 - 15318973

AN - SCOPUS:3242810485

VL - 14

SP - 725

EP - 730

JO - Obesity Surgery

JF - Obesity Surgery

SN - 0960-8923

IS - 6

ER -

Potteiger CE, Paragi PR, Inverso NA, Still C, Reed MJ, Strodel W et al. Bariatric surgery: Shedding the monetary weight of prescription costs in the managed care arena. Obesity Surgery. 2004 Jun 1;14(6):725-730. https://doi.org/10.1381/0960892041590999